Skip to main content
OpenTrials
Completed

NCT Number: NCT04986501

Clinical Evaluation of MucoPEG™ for Xerostomia

The purpose of this study is to evaluate the effectiveness of the oral rinse comparing to MucoPEG™ and Biotene®.

This is a randomized open-label crossover study with 42 patients receiving treatment. Patients will be randomly assigned to receive either the MucoPEG™ or the Biotene® Dry Mouth Gentle Oral Rinse in the first period. Patients will use the assigned oral rinse two times a day for two weeks. Patients will switch to the other treatment after a wash-out period of one week.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dry Mouth Mouth Diseases Salivary Gland Diseases Stomatognathic Diseases Xerostomia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ColoradoENT, Colorado Springs, Colorado, United States

Loading trial locations.

About this study

The purpose of this study is to compare MucoPEG™ and it temporal change to those of the Biotene® Dry Mouth Gentle Oral Rinse in patients with Xerostomia. The study will gather data on patient reported outcomes on the safety and performance of the product, mouth-feel qualities and any changes in dry mouth.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must have read, understood and signed an informed consent prior to entering the study.
  • Must be 18 years of age or older
  • Good general and mental health with, in the opinion of the investigator or their medically qualified designee, no clinically relevant or significant abnormalities found on examination of the oral cavity or in their medical history.
  • Participant with a Challacombe Scale score of 1 or higher
  • Participant agrees not to eat, drink, chew tobacco, chew gum, smoke, brush or floss their teeth for 2 hours prior to study visits
  • Participant agrees not to use any oral care products or any type of breath mint or lozenges for 2 hours prior to study visits
  • Participant agrees not to consume any food or liquid during the study visits, except for what is provided by the study research staff (e.g., water and treatments A and B during evaluation periods)
  • Participant agrees to using clinical oral care supplies provided by the investigators and no other products during the entire study
  • Understands and is willing and able to comply with all study procedures and restrictions

Exclusion criteria

  • Women who are pregnant or intending to become pregnant over the course of the study, or who are found to have a positive urine pregnancy test at the Screening Visit
  • Women who are breast-feeding
  • Participant is currently undergoing radiotherapy and/or chemotherapy.
  • Any condition the investigator identifies that may impede the participant's ability to properly participate in the study. For example, Alzheimer's Disease
  • Participant with untreated oral mucosal disease which in the opinion of the investigator could interfere with the study. For example, presence of oral ulceration.
  • Evidence of gross intra-oral neglect or need for extensive dental therapy
  • Denture wearer (complete dentures)
  • Participant on systemic parasympathetic medications (e.g. pilocarpine) for treating dry mouth, but the dose requirement of which is unstable
  • Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or to any of their stated ingredients
  • Participation in another clinical study (including studies of cosmetic products) or in receipt of an investigational drug within 14 days of the screening visit
  • Previous participation in this study
  • Recent history (within one year prior to screening visit) of alcohol or other substance abuse

Treatment and study plan

MucoPEG

Device

Experimental

Biotene

Device

Active Comparator

Primary outcomes

  1. Change in VAS for Mouth Dryness

    Time frame: baseline and 2 weeks, value at 2weeks minus value at baseline

    To demonstrate the effectiveness of MucoPEG is better than that of Biotene Dry Mouth Gentle Oral Rinse in relieving xerostomia. Effectiveness will be addressed using the Visual Analogue Scale (VAS). (VAS), where 0 is "Not Dry at All" and 10 is "Very Dry" VAS (before), which is measured before using any of the products on the first day of each treatment period, at Visit 2 or Visit 5. VAS (end), which is measured after the last dose of a product on the final day of each treatment period, at Visit 4 or Visit 7.

    Change in the rating of mouth dryness is the difference between the two time points, that is, VAS (end) - VAS (before).

  2. Dry Mouth Relief Questionnaires (DMRQ)

    Time frame: 2 weeks(at last visit)

    The effect of MucoPEG™ in relieving xerostomia, relative to that of Biotène was assessed using the Dry Mouth Relief Questionnaires (DMRQ). This questionnaire was given to the patients to answer the following question: "Does the product relieve the discomfort of dry mouth?" To answer the question, only one of the answer options is selected: 1. None/ (No Relief), 2. Not Enough, 3. Some/ Good, 4. Very Good, 5. Significant/ Excellent A favorable responses on the Dry Mouth Relief Questionnaire (DMRQ) include "4 - very good" or "5 - significant/excellent." The numbers are the number of patients who responded favorably at their last visit.

  3. Change in VAS for Tongue Dryness

    Time frame: baseline and 2 weeks, value at 2weeks minus value at baseline

    To demonstrate the effectiveness of MucoPEG is better than that of Biotene Dry Mouth Gentle Oral Rinse in relieving xerostomia. Effectiveness will be addressed using the Visual Analogue Scale (VAS). (VAS), where 0 is "Not Dry at All" and 10 is "Very Dry" VAS (before), which is measured before using any of the products on the first day of each treatment period, at Visit 2 or Visit 5. VAS (end), which is measured after the last dose of a product on the final day of each treatment period, at Visit 4 or Visit 7.

    Change in the rating of mouth dryness is the difference between the two time points, that is, VAS (end) - VAS (before).

Secondary outcomes

  1. Number of Participants With Treatment-related Adverse Events as Evaluated by the Principal Investigator

    Time frame: 2 weeks

    To evaluate the clinical safety of MucoPEG. Patient reported outcomes will be evaluated by the Principal Investigator.

  2. Dry Mouth Inventory (DMI) Questionnaire.

    Time frame: 2 weeks

    To demonstrate the effectiveness using the Dry Mouth Inventory (DMI). There are 8 Dry Mouth Inventory (DMI) questionaires as follows. 1. My mouth feels dry, 2. I have difficulty eating dry foods, 3. I get up at night to drink, 4. My mouth feels dry when eating a meal, 5. I sip liquids to aid in swallowing food, 6. I suck sweets or cough lollies to relieve dry mouth, 7. My lips stick to the teeth, 8. My tongue sticks to the roof of my mouth.

    Using a scale from "Disagree (0)" to "Strongly agree (3)". The scale has a minimum value of "0" and a maximum value of "24". The larger the scale, the more severe the dry mouth.

Sponsors and collaborators

Lead sponsor

SunBio, Inc.

Industry

Collaborators

  • NAMSA
  • Rudacure

Registry information

Acronym: CEMPEG

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Aug 2, 2021
Registry last updated
May 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.